Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Warnock

Showing results (321-330 of 371) with videos related to

Pageof 38
Sort By:
The American Journal of Physiology|June 1, 1996
Rapid redistribution and inhibition of renal sodium transporters during acute pressure natriuresisY Zhang, A K Mircheff, C B Hensley, et al.
JIMD Reports|January 9, 2015
Cognitive function in adults aging with fabry disease: a case-control feasibility study using telephone-based assessmentsVirginia G Wadley, Leslie A McClure, David G Warnock, et al.
Plos One|June 24, 2011
A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapyAndreas D Kistler, Justyna Siwy, Frank Breunig, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 1, 1997
Acute renal failure in the 21st century: recommendations for management and outcomes assessmentT D DuBose, D G Warnock, R L Mehta, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 4, 2014
Nondisease-specific problems and all-cause mortality among older adults with CKD: the REGARDS StudyC Barrett Bowling, John N Booth, Orlando M Gutiérrez, et al.
Molecular Genetics and Metabolism|August 12, 2016
Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry RegistryRobert J Hopkin, Gustavo Cabrera, Joel Charrow, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 10, 2010
Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) studyDavid G Warnock, Paul Muntner, Peter A McCullough, et al.
Kidney International|April 23, 2002
Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextranBeckie Michael, Daniel W Coyne, Steven Fishbane, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 7, 2014
Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) studyRikki M Tanner, David A Calhoun, Emmy K Bell, et al.
Molecular Genetics and Metabolism|January 10, 2012
Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry RegistryWilliam R Wilcox, Gabor E Linthorst, Dominique P Germain, et al.
Pageof 38

Showing results (321-330 of 371) with videos related to

Sort By:
Pageof 38
The American Journal of Physiology|June 1, 1996
Rapid redistribution and inhibition of renal sodium transporters during acute pressure natriuresisY Zhang, A K Mircheff, C B Hensley, et al.
JIMD Reports|January 9, 2015
Cognitive function in adults aging with fabry disease: a case-control feasibility study using telephone-based assessmentsVirginia G Wadley, Leslie A McClure, David G Warnock, et al.
Plos One|June 24, 2011
A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapyAndreas D Kistler, Justyna Siwy, Frank Breunig, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|May 1, 1997
Acute renal failure in the 21st century: recommendations for management and outcomes assessmentT D DuBose, D G Warnock, R L Mehta, et al.
Clinical Journal of the American Society of Nephrology : CJASN|October 4, 2014
Nondisease-specific problems and all-cause mortality among older adults with CKD: the REGARDS StudyC Barrett Bowling, John N Booth, Orlando M Gutiérrez, et al.
Molecular Genetics and Metabolism|August 12, 2016
Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry RegistryRobert J Hopkin, Gustavo Cabrera, Joel Charrow, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 10, 2010
Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) studyDavid G Warnock, Paul Muntner, Peter A McCullough, et al.
Kidney International|April 23, 2002
Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextranBeckie Michael, Daniel W Coyne, Steven Fishbane, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 7, 2014
Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) studyRikki M Tanner, David A Calhoun, Emmy K Bell, et al.
Molecular Genetics and Metabolism|January 10, 2012
Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry RegistryWilliam R Wilcox, Gabor E Linthorst, Dominique P Germain, et al.
Pageof 38